165 related articles for article (PubMed ID: 17106716)
1. Antigen-independent immune responses after dendritic cell vaccination.
Leonhartsberger N; Ramoner R; Putz T; Gander H; Rahm A; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2007 Jun; 56(6):897-903. PubMed ID: 17106716
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
3. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
5. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.
Rieser C; Ramoner R; Höltl L; Rogatsch H; Papesh C; Stenzl A; Bartsch G; Thurnher M
Urol Int; 1999; 63(3):151-9. PubMed ID: 10738185
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.
Hinkel A; Tso CL; Gitlitz BJ; Neagos N; Schmid I; Paik SH; deKernion J; Figlin R; Belldegrun A
J Immunother; 2000 Jan; 23(1):83-93. PubMed ID: 10687141
[TBL] [Abstract][Full Text] [Related]
8. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin.
Kim KD; Lee HG; Kim JK; Park SN; Choe IS; Choe YK; Kim SJ; Lee E; Lim JS
Immunology; 1999 Aug; 97(4):626-33. PubMed ID: 10457216
[TBL] [Abstract][Full Text] [Related]
15. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
16. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.
Wang J; Liao L; Tan J
Immunotherapy; 2012 Oct; 4(10):1031-42. PubMed ID: 23148755
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA
J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells induce CD4+ and CD8+ T-cell responses to Mycobacterium bovis and M. avium antigens in Bacille Calmette Guérin vaccinated and nonvaccinated cattle.
Hope JC; Kwong LS; Sopp P; Collins RA; Howard CJ
Scand J Immunol; 2000 Sep; 52(3):285-91. PubMed ID: 10972905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]